Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
| Autor: | Yongwu Shao, Ian R. McNicholl, Lauren Temme, Stefan Esser, Ignacio Pérez-Valero, Richard Haubrich, Antonella Castagna, David Piontkowsky, Nicolas A. Margot, Jean-Michel Molina, Federico Pulido, Josep M. Llibre |
|---|---|
| Přispěvatelé: | Perez-Valero, Ignacio, Llibre, Josep M, Castagna, Antonella, Pulido, Federico, Molina, Jean-Michel, Esser, Stefan, Margot, Nicola, Shao, Yongwu, Temme, Lauren, Piontkowsky, David, Mcnicholl, Ian R, Haubrich, Richard |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Anti-HIV Agents Medizin HIV Infections Quinolones 030312 virology Emtricitabine Tenofovir alafenamide Gastroenterology resistance Young Adult 03 medical and health sciences Abacavir Internal medicine Drug Resistance Viral Humans Medicine Pharmacology (medical) Aged 0303 health sciences M184I Alanine Elvitegravir/cobicistat/emtricitabine/tenofovir business.industry Elvitegravir Cobicistat virus diseases Clinical Science Middle Aged Resistance mutation switch tenofovir M184V Drug Combinations Regimen Infectious Diseases Mutation HIV-1 Female business medicine.drug |
| Zdroj: | Journal of Acquired Immune Deficiency Syndromes (1999) JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol instname |
| ISSN: | 1525-4135 |
| Popis: | Background: The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance mutations from historical genotypic reports when switching from a tenofovir disoproxil fumarate-based or abacavir (ABC)-based regimen was investigated. Setting: Phase IIIb, 48-week, open-label, single-arm, multicenter, clinical trial (NCT02616029). Methods: Virologically suppressed adults with HIV and documented M184V/I on historical genotypic records switched to E/C/F/TAF from a tenofovir disoproxil fumarate-based or ABC-based regimen. The primary end point was HIV-1 RNA of = 50 copies per milliliter (week 12); confirmatory HIV-1 RNA was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|